ALTA-2530 as a treatment for BOS and Chemical Lung Injury

ALTA-2530 is a novel inhaled formulation of recombinant IL-1Ra in development for bronchiolitis obliterans syndrome (BOS), which can arise following lung transplant or as a result of inhaled exposure to noxious chemicals. As an inhaled medication, ALTA-2530 can be delivered directly to the lungs to achieve higher levels of IL-1Ra in bronchioles than are feasible with systemic administration.

ALTA-2530 is the only inhaled IL-1Ra being developed to treat respiratory conditions. Inhaled IL1-Ra has been used in a small human study with positive results. Data from this study will be shared at a future medical meeting.

Altavant anticipates submitting an IND in 2023 to commence a clinical study with ALTA-2530 in post-lung transplant patients suffering from bronchiolitis obliterans syndrome. In addition, the company has partnered with the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) at the US Department of Health and Human Services (HHS) to investigate the utility of ALTA-2530 for the treatment of acute and chronic chemical lung injuries caused by the inhalation of sulfur mustard. This research is funded under the government’s Chemical Countermeasures Research Program (CCRP). The CCRP is responsible for overseeing the research and development of medical countermeasures that could prevent lethality and/or treat injuries resulting from toxic chemical exposure. The U.S. FDA granted ALTA-2530 orphan status for bronchiolitis obliterans syndrome under the Orphan Drug Designation program.

For more information, see also:

  • Publications related to ALTA-2530 here
  • Information on ALTA-2530’s mechanism of action here